Oric Pharmaceuticals Net Income vs. Cash Flow From Operations
| ORIC Stock | USD 11.86 0.34 2.95% |
Net Loss | First Reported 2019-03-31 | Previous Quarter -36.4 M | Current Value -32.6 M | Quarterly Volatility 9.3 M |
For Oric Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oric Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oric Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oric Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oric Pharmaceuticals over time as well as its relative position and ranking within its peers.
Check out Your Equity Center. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oric Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Oric Pharmaceuticals Cash Flow From Operations vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Oric Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Oric Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Oric Pharmaceuticals is rated below average in net income category among its peers. It is rated below average in cash flow from operations category among its peers . At present, Oric Pharmaceuticals' Net Loss is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Oric Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Oric Cash Flow From Operations vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Oric Pharmaceuticals |
| = | (127.85 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Oric Pharmaceuticals |
| = | (112.66 M) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Oric Cash Flow From Operations Comparison
Oric Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers.
Oric Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Oric Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Oric Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Oric Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Oric Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 435.9 K | 457.6 K | |
| Operating Income | -128.6 M | -122.2 M | |
| Income Before Tax | -115.1 M | -109.3 M | |
| Total Other Income Expense Net | 17.3 M | 18.2 M | |
| Net Loss | -80.2 M | -84.2 M | |
| Net Loss | -115.1 M | -109.3 M | |
| Net Interest Income | 3 M | 3.2 M | |
| Interest Income | 3 M | 3.2 M | |
| Net Loss | -115.1 M | -120.8 M | |
| Income Tax Expense | 2.7 M | 4.9 M | |
| Non Operating Income Net Other | 13.5 K | 12.8 K | |
| Change To Netincome | 16.7 M | 10 M | |
| Net Loss | (2.11) | (2.21) | |
| Income Quality | 1.01 | 0.92 |
Oric Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Oric Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Oric Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Oric Pharmaceuticals' important profitability drivers and their relationship over time.
Oric Pharmaceuticals Earnings Estimation Breakdown
The calculation of Oric Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Oric Pharmaceuticals is estimated to be -0.3811 with the future projection ranging from a low of -0.54 to a high of -0.3. Please be aware that this consensus of annual earnings estimates for Oric Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.54 Lowest | Expected EPS | -0.3 Highest |
Oric Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Oric Pharmaceuticals' value are higher than the current market price of the Oric Pharmaceuticals stock. In this case, investors may conclude that Oric Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Oric Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 15 | 74.13% | 0.0 | -0.3811 | -1.71 |
Oric Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Oric Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Oric Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Oric Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Oric Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Oric Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Oric Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Oric Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Oric Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-13 | 2025-09-30 | -0.4 | -0.33 | 0.07 | 17 | ||
2025-08-12 | 2025-06-30 | -0.44 | -0.47 | -0.03 | 6 | ||
2025-05-05 | 2025-03-31 | -0.44 | -0.42 | 0.02 | 4 | ||
2025-03-10 | 2024-12-31 | -0.5084 | -0.51 | -0.0016 | 0 | ||
2024-11-04 | 2024-09-30 | -0.4717 | -0.49 | -0.0183 | 3 | ||
2024-08-12 | 2024-06-30 | -0.41 | -0.45 | -0.04 | 9 | ||
2024-05-06 | 2024-03-31 | -0.44 | -0.37 | 0.07 | 15 | ||
2024-03-11 | 2023-12-31 | -0.49 | -0.49 | 0.0 | 0 | ||
2023-11-06 | 2023-09-30 | -0.46 | -0.44 | 0.02 | 4 | ||
2023-08-10 | 2023-06-30 | -0.57 | -0.5 | 0.07 | 12 | ||
2023-05-08 | 2023-03-31 | -0.54 | -0.53 | 0.01 | 1 | ||
2023-03-16 | 2022-12-31 | -0.54 | -0.52 | 0.02 | 3 | ||
2022-11-07 | 2022-09-30 | -0.55 | -0.63 | -0.08 | 14 | ||
2022-08-11 | 2022-06-30 | -0.6 | -0.51 | 0.09 | 15 | ||
2022-05-09 | 2022-03-31 | -0.57 | -0.59 | -0.02 | 3 | ||
2022-03-21 | 2021-12-31 | -0.57 | -0.58 | -0.01 | 1 | ||
2021-11-08 | 2021-09-30 | -0.58 | -0.47 | 0.11 | 18 | ||
2021-08-10 | 2021-06-30 | -0.49 | -0.57 | -0.08 | 16 | ||
2021-05-06 | 2021-03-31 | -0.48 | -0.45 | 0.03 | 6 | ||
2021-03-23 | 2020-12-31 | -0.46 | -0.84 | -0.38 | 82 | ||
2020-11-05 | 2020-09-30 | -0.39 | -0.41 | -0.02 | 5 | ||
2020-08-05 | 2020-06-30 | -0.4 | -0.51 | -0.11 | 27 | ||
2020-05-20 | 2020-03-31 | -0.26 | -4.46 | -4.2 | 1615 | ||
2020-02-28 | 2019-12-31 | 0 | -0.08 | -0.08 | 0 |
Use Oric Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oric Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oric Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Oric Pharmaceuticals Pair Trading
Oric Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Oric Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oric Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oric Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oric Pharmaceuticals to buy it.
The correlation of Oric Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oric Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oric Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oric Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Oric Pharmaceuticals position
In addition to having Oric Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investment Grade ETFs Thematic Idea Now
Investment Grade ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Investment Grade ETFs theme has 331 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investment Grade ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
To fully project Oric Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Oric Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Oric Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.